Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program

September 8, 2010 By Bio-Medicine.Org

MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ — MAP
Pharmaceuticals, Inc. (Nasdaq:
MAPP) today announced that all non-asthmatic patients and a
subset of asthmatic patients have completed 12 months of treatment
in the open-label safety trial of LEVADEX™. In addition, the
Company has completed patient treatment in a thorough QT trial, the
last trial necessary to support a New Drug Application (NDA) for
LEVADEX. At this time, all patients have been enrolled in the
Company’s clinical trials in support of an NDA, which the Company
expects to submit in the first half of 2011.  LEVADEX is a
novel orally inhaled migraine therapy that has completed Phase 3
efficacy development for the acute treatment of migraine.

The Company also gave an update of its LEVADEX clinical
development program:

Open-label safety trial: To date, more than 400 patients
have completed at least six months of treatment and more than 200
patients have completed twelve months of treatment. All
non-asthmatic patients and a subset of asthmatic patients have
completed treatment.  The remaining patients are expected to
complete treatment in 2010.  The Company and an independent
data monitoring committee (DMC) recently completed an interim
safety review of all patients, including asthmatics. In this trial,
LEVADEX has been well tolerated and no drug-related serious adverse
events have been reported. To date, no clinically significant
trends have been reported for LEVADEX in the evaluation of
cardiovascular measurements (as measured by electrocardiogram,
echocardiogram and chest x-ray) and pulmonary function (as measured
by DLco and FEV1). This 12 month open-label, long- term safety
extension of the Company’s Phase 3 FREEDOM-301 trial is designed to
evaluate overall safety of LEVADEX in at least 300 patients for six
months and 150 patients for 12 months, including asthmatics.

‘/>”/>

SOURCE

Related Articles Read More >

Connected device design for the real world: Managing the development process
A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech